1. Fixed dose-rate infusion of gemcitabine in combination with cisplatin and UFT in advanced carcinoma of the pancreas

   • J. Feliu
   • J. García Sáenz
   • M. González Barón

   Original Article 11 January 2006 Pages: 419 - 426

2. Phase I and pharmacokinetic study of weekly NV06 (Phenoxodiol™), a novel isoflav-3-ene, in patients with advanced cancer

   • Paul L. de Souza
   • Winston Liauw
   • Laurence G. Howes

   Original Article 04 February 2006 Pages: 427 - 433

   

3. Repression of telomerase reverse transcriptase mRNA and hTERT promoter by gambogic acid in human gastric carcinoma cells

   • Jun Yu
   • Qing-Long Guo
   • Xiaotang Wang

   Original Article 10 February 2006 Pages: 434 - 443

   

4. The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling

   • Ryan Williams
   • Amanda F. Baker
   • Garth Powis

   Original Article 17 February 2006 Pages: 444 - 450

   

5. The tumor specific cytotoxicity of dihydronitidine from Toddalia asiatica Lam

   • Hironori Iwasaki
   • Hirosuke Oku
   • Masashi Inafuku

   Original Article 08 February 2006 Pages: 451 - 459

   

6. Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells

   • Junichi Kurebayashi
   • Sumiko Okubo
   • Hiroshi Sonoo

   Original Article 25 January 2006 Pages: 460 - 470

   

7. Trichostatin A sensitizes TRAIL-resistant myeloma cells by downregulation of the antiapoptotic Bcl-2 proteins

   • Tamer E. Fandy
   • Rakesh K. Srivastava

   Original Article 25 January 2006 Pages: 471 - 477

   

8. Distribution of 5-aminolevulinic acid derivatives and induced porphyrin kinetics in mice tissues

   • Gabriela Di Venosa
   • Alcira Batlle
   • Adriana Casas

   Original Article 17 February 2006 Pages: 478 - 486

   

9. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine

   • Søren Astrup Jensen
   • Jens Benn Sørensen

   Original Article 18 January 2006 Pages: 487 - 493

10. Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea

    • K. Takasuna
    • T. Hagiwara
    • T. Kamataki

    Original Article 25 January 2006 Pages: 494 - 503

    

11. Adjuvant intra-arterial 5-fluoruracil, leucovorin, epirubicin and carboplatin with or without systemic gemcitabine after curative resection for pancreatic adenocarcinoma

    • Maurizio Cantore
    • Giovanni Serio
    • Giammaria Fiorentini

    Original Article 22 April 2006 Pages: 504 - 508

    

12. Pharmacology of the paclitaxel–cisplatin, gemcitabine–cisplatin, and paclitaxel–gemcitabine combinations in patients with advanced non-small cell lung cancer

    • J. R. Kroep
    • E. F. Smit
    • G. J. Peters

    Original Article 07 March 2006 Pages: 509 - 516

    

13. Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism

    • B. J. Cusack
    • H. Gambliel
    • R. D. Olson

    Original Article 23 March 2006 Pages: 517 - 526

    

14. Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer

    • J. Feliu
    • G. Martín
    • M. Gonzalez-Barón

    Original Article 23 March 2006 Pages: 527 - 531

15. Pharmacokinetics of N-2-chloroethylaziridine, a volatile cytotoxic metabolite of cyclophosphamide, in the rat

    • Hong Lu
    • Kenneth K. Chan

    Original Article 10 February 2006 Pages: 532 - 539

    

16. Hypoxia-mediated fenretinide (4-HPR) resistance in childhood acute lymphoblastic leukemia cells

    • Bo Yang
    • Lingling Fan
    • Qiaojun He

    Original Article 07 March 2006 Pages: 540 - 546

    

17. Gemcitabine resistance due to deoxycytidine kinase deficiency can be reverted by fruitfly deoxynucleoside kinase, DmdNK, in human uterine sarcoma cells

    • Lars Petter Jordheim
    • Carlos M. Galmarini
    • Charles Dumontet

    Original Article 04 February 2006 Pages: 547 - 554

    

18. Front-line paclitaxel and topotecan chemotherapy in advanced or metastatic non-small-cell lung cancer: a phase II trial

    • G. P. Stathopoulos
    • C. Katis
    • E. Dimou

    Original Article 07 March 2006 Pages: 555 - 560